Drug Topics December 24, 2023
Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.
This year was a year of firsts in the immunization space1: In addition to the first vaccines to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in older adults and the first RSV vaccine for use in pregnant people to protect newborns, 2023 saw the first vaccine for adults at increased risk of exposure to chikungunya virus made its debut. Additional approvals included a new meningococcal vaccine that simplifies a complex immunization schedule.
References
1. 2023 biological license application approvals. FDA. Reviewed November 27, 2023. Accessed November 28, 2023. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-approvals
2. FDA approves first respiratory syncytial virus (RSV) vaccine. News release. FDA. May...
Today's Sponsors
Today's Sponsor